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Introduction
Rhabdomyosarcoma (RMS) is the most common pedi-
atric soft tissue sarcoma usually diagnosed in the first
decade of life [1]. RMS can be divided into four sub-
types with embryonal RMS (ERMS) and alveoral
RMS (ARMS) being predominant [1]. A distinguished
characteristic of ARMS is an occurrence of chromoso-
mal translocation leading to expression of fusion pro-
teins PAX3-FKHR (t(2:13)(q35:q14)) and PAX7-
FKHR (t(1:13)(p36:q14)) [2,3]. Expression of these
proteins has been correlated with a significantly worse
prognosis of ARMS patients, seen as a higher risk of
relapse and metastasis [4-7].
MET protooncogene, encoding receptor for Hepato-
cyte Growth Factor (HGF) has been shown to influence
various aspects of cell biology. Interactions between
MET and HGF are essential in physiological (e.g.
embryogenesis, muscle development, bone remodeling)
and pathological (e.g. tumor development) settings [8,9].
Over-expression of MET receptor is observed in a
variety of tumor cells. Increased MET receptor expres-
sion may be a result of MET gene amplification [10],
induction by other oncogenes, such as RAS [11], PAX3-
FKHR [7] or transiently due to hypoxia-activated tran-
scription [12]. In transformed tissues, activation of MET
by HGF triggers tumor growth and metastasis [13].
MET signaling exhibits profound effects on the
invasive behavior of a variety of tumor cells by induc-
ing production of various proteases such the uroki-
nase-type plasminogen activator-dependent proteolyt-
ic network [14,15], matrix metalloproteinases and
metalloproteinase inhibitors [15]. MET activation
enhances transendothelial migration of cancer cells by
modulating expression of adhesion molecules both on
cancer cells and endothelium [16-19].
The role of MET receptor activation in pathogene-
sis of RMS has been documented. Activation of MET
has been shown to influence proliferation, survival and
migration of RMS cells [20,21]. Recently, inducible
down-regulation of MET receptor obtained with
lentivirus expressing an anti-MET short hairpin RNA
has been demonstrated to significantly affect RMS
cells biology, particularly cell proliferation and apop-
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tosis [22]. However, the effect of MET downregulation
on metastatic behavior of RMS has not been studied in
details. Thus, to better understand the role of MET recep-
tor in metastasis of RMS we created cell lines with sta-
bly downregulation of MET receptor and studied their
ability to migrate, to secrete extracellular matrix digest-
ing enzymes, and to repopulate bone marrow in vivo.
Materials and methods
Cell lines. RMS cell lines used in this study (SMS-CTR-ERMS
and RH30-ARMS) were generously provided by prof. M. Z. Rata-
jczak (University of Louisville, KY, USA) and were maintained in
DMEM (Gibco BRL) supplemented with 10% heat-inactivated
FBS (Gibco), 100 IU/ml penicillin, 10 mg/ml streptomycin
(Gibco). Cells were cultured at 37°C, 5% CO2, 95% humidity.
They were split twice a week with medium change.
Lentiviral vectors construction, production and in vitro trans-
duction. The pENTR vector containing the MET- or LacZ-specif-
ic short hairpin RNA (shRNA) was recombinated with pLenti6/
BLOCK-iT™-DEST expression vector (Invitrogen). High titer
lentiviral vector stock was produced in 293FT cells by transient
lipofection of the pLenti6-GW/U6-shRNA and packaging plasmids
pLP1, pLP2, and pLP/VSVG. RMS cells were transduced directly
with viral supernatants and subsequently selected with blasticidin.
RMS cells transduced with anti MET shRNA were indexed with
shMET, while those transduced with anti LacZ – with shLacZ
label.
Cell Proliferation assessment by MTT Assay. The MTT assay
was performed according to the manufacturer's recommendations
(Promega). Briefly, cells were seeded in 96-well plates at 104/well
in 100 μl of DMEM medium containing 10% FBS. After 24, 48 and
72 hours, 10 μl of CellTiter 96 Aqueous One Solution reagent were
added to each well and plates were incubated for 3-4 hours. Subse-
quently, plates were read at 490 nm using the ELx800 Universal
Microplate Reader (Bio-tek) and analyzed with KC4 v3.0 with Pow-
erReports software (Bio-tek). The experiment was done two times. 
Western blot. RMS cells were lysed on ice in M-Per lysing buffer
(Pierce) containing protease and phosphatase inhibitors (Sigma).
Subsequently, the extracted proteins were separated on a 12% sodi-
um dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE)
gel and fractionated proteins were transferred into a PVDF mem-
brane (BioRad). The membrane was incubated with 1% BSA for 1
hour and then overnight with primary antibodies anti-MET 1:1000
clone sc-161 (Santa Cruz Biotech.) and GAPDH as a control
1:10000 clone 2118 (Cell Signaling, Danvers, Massachusetts,
USA). Subsequently proteins were detected with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse or anti-rabbit IgG sec-
ondary antibody (Santa Cruz Biotech). The membranes were devel-
oped with an enhanced chemiluminescence (ECL) reagent (Amer-
sham Life Sciences), dried and subsequently exposed to the Hyper-
Film (Amersham Life Sciences). An equal loading was evaluated
by reprobing with an anti GAPDH antibody (Santa Cruz Biotech).
Chemotaxis assay. The directional movement of cells towards
HGF gradient was evaluated using modified Boyden's chamber
with 8 μm pore polycarbonate membrane inserts (Costar Tran-
swell; Costar-Corning). Cells were detached with 0.25% trypsin,
washed and suspended in DMEM containing 0.5% BSA and seed-
ed into the upper chamber of an insert at a density of 2.5 × 104 cells
in 100 μl. The lower chamber was filled with pre-warmed medium
containing HGF (20 ng/ml). 0.5% BSA DMEM medium was used
as a negative control. After 24 hours, inserts were removed from
the transwells, cells were fixed with methanol. Cells which did not
migrate were scraped off with cotton wool from the upper mem-
brane and cells that had transmigrated to the lower side of the
membrane were stained with Wright solution and counted under
high power field (HPF) with an inverted microscope. Five fields
were counted each time and the mean number of cells per HPF was
calculated. The experiments were done twice in duplicates.
"Wound healing" assay. For the wound healing experiment, cells
were seeded in 6 well plates and allowed to grow to complete con-
fluence. Subsequently, a plastic pipette tip was used to scratch the
cell monolayer to create a clear area, and the wounded cell layer
was washed with fresh medium to remove loose cells. The cells
were then maintained in DMEM containg 0.5% BSA with or with-
out HGF (20 ng/ml) or in DMEM with 10% FBS as a positive con-
trol. After 72 hours cells were stained with Wright solution and pic-
tures were taken. The experiments were repeated twice.
Invasion assay. GFR Matrigel invasion inserts (BD Biosciences)
were rehydrated with DMEM for 2 hours and transferred to the
wells containing medium with chemoattractant (HGF 20 ng/ml) or
medium alone (DMEM with 0.5% BSA) as a control. Cells were
harvested by trypsinization, washed, resuspended in DMEM medi-
um containing 0.5% BSA and seeded at density of 2.5 × 104 in 0.5
ml to the inside of the inserts. After 24 hours, cells that invaded the
Matrigel were counted on the undersides of filters after fixation
and staining with Wright solution. As a control of invasion the
same number of control inserts (no GFR Matrigel coating) was
applied. The experiments were carried out twice in duplicates.
RNA Extraction and Reverse Transcription. Total RNA was
extracted using RNeasy Mini Kit (Qiagen) followed by DNAse
treatment (Promega). The reverse polymerase transcription was
performed using MMLV reverse transcriptase (Invitrogen) accord-
ing to manufacturer's protocol.
Murine models. Short-term assay was performed as described
previously [23]. Briefly, 5 × 106 SMS-CTR and 5 × 106 RH30 cells
were injected supraorbitaly into 6-8 weeks NOD-SCID mice, treat-
ed a day before with 300 cGy. Each experimental group comprised
of 3-5 animals and the experiments were repeated twice. After 24
hours the mice were killed and bone marrow cells from two legs of
each mouse were harvested. The cells from each leg were kept sep-
arately and total RNA was isolated using RNAeasy Kit (Qiagen).
The reverse polymerase transcription was performed using MMLV
reverse transcriptase (Invitrogen). The level of RMS cells homing
to bone marrow was evaluated by Real-Time PCR using human
GAPDH specific primers-probe set (Hs99999905_m1; Applied
Biosystems). The control experiment showed no cross-reactivity
with murine GAPDH.
For long term-assay 5 × 106 RMS cells were injected subcuta-
neously into 6-8 weeks NOD-SCID mice. Each experimental
group comprised of 3-5 animals and experiments were repeated
twice. After 30 days mice were killed, tumors were harvested and
were weighted. 
Statistical analysis. Statistical analysis was performed using a
one-way non-paired Student's t-test with Microsoft Excel.
Results
Creation of MET negative cell lines
We have tested two different siRNA – MET#1 and
MET#2, and efficient inhibition of MET expression
(more than 80%) was obtained at both mRNA and pro-
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tein level (Fig. 1A). Based on these results MET
shRNA was created using MET#1 sequence and
cloned into a pLenti6-GW/U6-shRNA vector. Subse-
quently, RMS cells were transduced with MET shRNA
expressing virus. We observed over 80% downregula-
tion of MET expression both at the mRNA and protein
level in transduced cells. As a control of lacZ shRNA
expressing cell lines were created that possessed simi-
lar MET receptor expression to wild type cells (Fig.
1B).
Proliferation and morphology of MET negative
cells
To study the influence of MET downregulation on
RMS proliferation, cells were cultured in the presence
of FBS and growth curve was generated. We did not
observe any differences between proliferation rate of
RMSWT (wild-type; non-transfected) and RMSshMET
(transduced with lentivirus) cell lines (Fig. 2A). How-
ever, serum-deprived conditions caused small but
noticeable changes in morphology of RH30shMET cells
which became more elongated (Fig. 2B). 
MET negative cells possess decreased potential
to migrate and to invade extracellular matrix in
vitro
Since cell migration and invasion are important parts
of metastatic behavior, we examined how inhibition of
MET expression influenced these processes. First,
direct migration towards HGF gradient was evaluated
using modified Boyden chambers. RMS cells with
downregulated MET expression were almost com-
pletely unresponsive to stimulation with HGF gradi-
ent. At the same time, control cells showed strong
migratory response to HGF (Fig. 3A).
Since the ability to migrate through extracellular
matrix (ECM) is inseparable feature of metastatic
tumors, we studied how silencing of HGF-MET sig-
naling affects the potential of RMS cells to invade
through matrigel coated Boyden chamber inserts. We
observed complete inhibition of both SMS-CTRshMET
and RH30shMET cells ability to cross through the
matrigel (Fig. 3B). This was paralleled by downregu-
lation of mRNA expression for a protease responsible
for degrading ECM. We noticed that RMSshMET cells
had three to five folds lower expression of MMP9 in
comparison to control cells (Fig. 3C). 
Using "wound healing" assay we checked the
motility of RMS cells in response to HGF. RMSshMET
cells cultured in the presence of HGF did not show any
motile response in contrary to RMSWT cells, which
responded rapidly to HGF treatment. However, both
RMSWT and RMSshMET cells possessed similar ability
to migrate when cultured in 10% FBS (Fig. 3D). 
Reduced ability of shMET cells to engraft into
bone marrow and to grow in vivo
To evaluate homing of RMSshMET tumors into bone
marrow cavities, we injected them into NOD-SCID
mice, and as a control, we used wild type RMS cells.
After 24 hours, bone marrow from two legs was har-
vested and presence of human cells in the murine bone
marrow was estimated using qRT-PCR. A significant
decrease (two to four fold) in seeding efficiency of
RMSshMET tumors was observed (Fig. 4A).
5 × 106 MET – negative and – positive cells were
injected s.c. into NOD-SCID mice and their ability to
grow was evaluated after 30 days. Significantly, the
decreased tumor size of both SMS-CTRshMET and
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Fig. 1. Creation of MET negative RMS cell lines. Efficiency of
MET downregulation was analyzed at mRNA (A and B – upper
panels) and protein levels (A and B – lower panels). Cells tran-
siently transfected with MET siRNA (A) or stable transduced with
MET shRNA containing virus (B) showed almost complete down-
modulation of MET receptor expression, *p<0.05. 
Fig. 2. Influence of MET downregulation on proliferation and
morphology of RH30. ownregulation of MET receptor did not
influence growth of SMS-CTRshMET and RH30shMET cells (A).
RH30shMET cells cultured in serum deprived conditions showed
small morphological changes (pointed by arrows) not observed in
wild type cells (B). Experiments were done two times.
RH30shMET cells was noticed (Fig. 4B) with RMSshMET
tumors being on average two to four times smaller than
RMSWT tumors.
Discussion
In this study, we have shown that inhibition of MET
expression by RNA interference has strong influence
on metastatic behavior of RMS cells both in vitro and
in vivo. Thus, we further confirmed the importance of
MET receptor in the biology of RMS tumors [20-22].
Using RNAi we created RMS cell lines of both
ERMS and ARMS subtypes lacking MET receptor
expression as assessed by qRT-PCR and western blot-
ting and determined their potential to migrate, invade
and secrete ECM degrading enzymes in vitro and to
grow and metastasize into bone marrow in vivo.
HGF-MET axis has been shown to stimulate prolif-
eration of RMS cells whereas blocking of the axis
inhibited this effect [22]. However, in our study we did
not observe any influence of MET downregulation on
mitogenic potential of RMS cells. We tested
RMSshMET cells growth and we found that proliferation
rate of RMSshMET cell lines was similar to RMSWT
counterparts. However, small changes in RMSshMET
cells morphology in serum-free conditions were
observed. The discrepancy between these two studies
could be due to different culture conditions or differ-
ences in a way of MET downregulation (constitutive
inhibition in the present study versus inducible inhibi-
tion in study by Taulli and coworkers [22]).
MET receptor activates the motility of RMS cells,
one of the features responsible for invasive phenotype
of RMS [21,24]. Using RMSshMET cells we showed
that blocking of MET expression completely inhibits
transmigration of both ERMS and ARMS cells
through ECM, which had been shown previously [22].
However, in the previous study the mechanisms
responsible for this action had not been examined. In
the current study we evaluated the expression of
matrix metaloproteinases responsible for degrading
ECM. We noticed a strong reduction in MMP9 expres-
sion in RMSshMET cells in comparison to the wild type
cells.
Jankowski and co-workers postulate that HGF-
MET axis may play an important role in RMS bone
marrow metastasis [21]. Thus, the ability of MET neg-
ative RMS cells to populate bone marrow, one of the
primary sites of RMS metastasis [1], was studied in
this work. We provided here the direct proof that MET
receptor is an important factor facilitating bone mar-
row engraftment of RMS cells.
In this study, we also confirmed and extended find-
ings that MET downregulation blocks in vivo growth
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Fig. 3. MET downregulation decreases HGF-dependent overall
motility and invasive behavior of RMS cells in vitro. Directional
movement of RMS cells toward HGF (20 ng/ml) were studied
using modified Boyden's chambers (A). Both ERMS and ARMS
cell lines showed strong migratory dependence on the presence of
MET receptor as both SMS-CTRshMET and RH30shMET cells lines
possessed only very weak chemotactic activity toward HGF in
comparison to controls, *p<0.05. Experiment was repeated two
times in duplicate. HGF-mediated invasion of RMS cells was com-
pletely abolished in shMET expressing cell lines as measured by
their ability to migrate through GFR Matrigel invasion inserts (B).
Expression of invasion-related genes was measured in RMS cells
cultured for 72 hours in a presence of HGF. Downregulation of
MMP9 expression was observed (C) (control – grey bars, shMET
– open bars), * p<0.05. MET positive and MET negative cells
were grown to confluence, scratched and stimulated with 20 ng/ml
HGF or 10% FBS (D). Only control cells had the ability to migrate
and close the "wound" when stimulated with HGF. However, both
WT and shMET cells were equally responsive to FBS treatment.
Experiment was repeated twice with similar results.
Fig. 4. In vivo homing and growth of RMS cells is dependent on
MET expression. NOD-SCID model of human RMS was used to
study the role of MET receptor in facilitating metastatic behavior
of RMS cells. Bone marrow involvement was studied in short-term
assay by injecting 5 × 106 tumor cells supraorbitaly into sublethaly
irradiated NOD-SCID mice and harvesting bone marrow 24 hours
later. Presence of human cells was calculated using qRT-PCR and
human GAPDH primer set (A). Tumor growth of both ERMSshMET
cells and ARMSshMET was studied by injecting 5 × 106 tumor cells
subcutaneously and measuring the tumor weight 30 days later (B).
Decrease in both seeding efficiency and tumor size of RMSshMET
cells was seen when compared to controls, * p<0.05.
of both ARMS and ERMS cells. MET negative tumors
were on average two times smaller than their wild type
counterparts. It might derive from the lower number of
blood vessels in these tumors. This phenomena is still
under investigation. 
In conclusion, MET receptor plays an exceptionally
important role in facilitating metastasis of RMS cells
and also blocking of HGF-MET axis could be used in
the future as a potential therapeutic option to treat RMS
patients at more advanced and metastatic stages.
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